183 related articles for article (PubMed ID: 38140046)
1. Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy.
Fernández-Rubio B; Herrera-Hidalgo L; de Alarcón A; Luque-Márquez R; López-Cortés LE; Luque S; Gutiérrez-Urbón JM; Fernández-Polo A; Gutiérrez-Valencia A; Gil-Navarro MV
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140046
[TBL] [Abstract][Full Text] [Related]
2. Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy.
Loeuille G; D'Huart E; Vigneron J; Nisse YE; Beiler B; Polo C; Ayari G; Sacrez M; Demoré B; Charmillon A
Antibiotics (Basel); 2022 Mar; 11(4):. PubMed ID: 35453211
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices.
Chen IH; Martin EK; Nicolau DP; Kuti JL
Clin Ther; 2020 Apr; 42(4):606-613. PubMed ID: 32139176
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Weber C; Schultze T; Göttig S; Kessel J; Schröder A; Tietgen M; Besier S; Burbach T; Häussler S; Wichelhaus TA; Hack D; Kempf VAJ; Hogardt M
Microbiol Spectr; 2022 Oct; 10(5):e0169722. PubMed ID: 36190424
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
Sader HS; Castanheira M; Duncan LR; Mendes RE
Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
[TBL] [Abstract][Full Text] [Related]
7. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
Prescott WA; Gentile AE; Nagel JL; Pettit RS
P T; 2011 Nov; 36(11):723-63. PubMed ID: 22346306
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
Mirza HC; Hortaç E; Koçak AA; Demirkaya MH; Yayla B; Güçlü AÜ; Başustaoğlu A
J Glob Antimicrob Resist; 2020 Mar; 20():334-338. PubMed ID: 31568882
[TBL] [Abstract][Full Text] [Related]
9. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
11. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS
Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763
[TBL] [Abstract][Full Text] [Related]
12. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
13. Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000).
Jones RN; Kirby JT; Beach ML; Biedenbach DJ; Pfaller MA
Diagn Microbiol Infect Dis; 2002 Jul; 43(3):239-43. PubMed ID: 12106958
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
[No Abstract] [Full Text] [Related]
15. In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2012-2021.
Lee YL; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2023 Aug; 62(2):106867. PubMed ID: 37244423
[TBL] [Abstract][Full Text] [Related]
16. Stability Studies of Antipyocyanic Beta-Lactam Antibiotics Used in Continuous Infusion.
Curti C; Souab HK; Lamy E; Mathias F; Bornet C; Guinard B; Fersing C; Primas N; Albanèse J; Vanelle P
Pharmazie; 2019 Jun; 74(6):357-362. PubMed ID: 31138374
[TBL] [Abstract][Full Text] [Related]
17. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.
Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G
J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the stability of antimicrobial agents in elastomeric devices for outpatient parenteral antimicrobial therapy services based on NHS Yellow Cover Document standards.
Jenkins A; Shanu S; Jamieson C; Santillo M
Eur J Hosp Pharm; 2022 Nov; 29(6):304-307. PubMed ID: 33990388
[TBL] [Abstract][Full Text] [Related]
19.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
20. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).
Viaene E; Chanteux H; Servais H; Mingeot-Leclercq MP; Tulkens PM
Antimicrob Agents Chemother; 2002 Aug; 46(8):2327-32. PubMed ID: 12121900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
